SAFETY INFORMATION FOR PATIENTS

Your safety guide for SYFOVRE®▼(pegcetacoplan)

- This guide provides important safety information for people who have been prescribed SYFOVRE® [Sye-fo-vree] for the treatment of geographic atrophy, an advanced form of age-related macular degeneration.
- SYFOVRE® contains the active ingredient pegcetacoplan [peg-set-a-koé-plan] and it is injected into your eye by a healthcare professional.
- ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may experience. See page 4 for how to report side effects.

An **audio version** of the information in this guide is available here: **apellis.au/our-product**

Important safety information

You should not receive SYFOVRE® if:

- You have an active eye infection or inflammation inside the eye
- You are allergic to pegcetacoplan or any of the other ingredients in this medicine

If you are unsure about any of the above, talk to your eye specialist before starting treatment.

SYFOVRE® may cause side effects, although not everyone will experience them.

Some important side effects that may occur include:

- A disease that involves the formation and leakage of new blood vessels in the central part of the retina (macula) at the back of the eye (wet, neovascular or exudative age-related macular degeneration)
- An infection in the eye (endophthalmitis)
- A temporary increase in eye pressure (increase in intraocular pressure)
- **Inflammation inside the eye** (intraocular inflammation)
- A severe form of inflammation of blood vessels in the back of the eye (retinal vasculitis)
- Serious allergic reactions (hypersensitivity/anaphylaxis)

You should contact your eye doctor or seek immediate medical care if you experience any of the following symptoms, which may be a sign of one of the important side effects listed on page 2:

Eye pain or increased discomfort

Blurred, distorted, or cloudy vision

Worsening redness and/or swelling in the eye

Increased sensitivity to light

A blind dark spot in centre of vision

A sudden loss of or change in vision

Increased number of small particles (floaters)

Rash and/or hives

Difficulty breathing, swelling of throat, lips, or tongue

Other side effects may occur while taking SYFOVRE®. For a list of all potential side effects, please read the **Consumer Medicine Information** that comes with your SYFOVRE®. Ask your eye doctor, or access it here: apellis.au/our-product

Reporting side effects

Report side effects to your **eye doctor**. This enables your doctor to make any necessary adjustments to your treatment and helps ensure your safety and well-being.

You may also report any side effects you experience to the Therapeutic Goods Administration by visting: tga.gov.au/reporting-problems or to Apellis at: 1800 879 456

Contact your eye doctor with questions, or you may submit questions to Apellis Medical Information at: medinfo@apellis.com

This educational material is developed and provided by Apellis Australia Pty Ltd as a mandatory condition of the Marketing Authorisation in order to further minimise important selected risks. This material is applicable in Australia.

Apellis Australia Pty Ltd. Level 3, 141 Camberwell Rd, Hawthorn East, VIC, 3123, Australia. ABN 87600 316 612.Preparation Date: July 2025. VV-PVG-000669.